ABL1 and triple-negative breast carcinoma: It also raises questions about MMR function in solid tumors with hyperactive ABL1, such as subsets of melanoma or triple-negative breast cancer (Srinivasan and Plattner, 2006; Srinivasan et al., 2008; Ganguly et al., 2012; Ganguly and Plattner, 2012).